AstraZeneca’s GALAXY Studies And Plans For Crestor’s Ongoing Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Company executives discuss on-going efforts to differentiate Crestor in the increasingly crowded cholesterol-lowering market.
You may also be interested in...
Amid The Lipitor Scuffle, What’s Next For Crestor?
Expiration of the Lipitor patent puts tremendous pressure on AstraZeneca’s bestselling statin, Crestor, which accounts for 20% of total revenues. AstraZeneca insists the drug’s value proposition will enable it to withstand the onslaught, but analysts expect a gradual chipping away at market share.
Will JUPITER Change Statin Use?
Positive results from AstraZeneca’s outcomes trial of Crestor have all eyes on whether statin utilization will undergo a paradigm shift.
AstraZeneca Revitalizes Crestor With Atherosclerosis Ad Campaign
Company makes hay from Merck/Schering-Plough's failed Vytorin atherosclerosis trial.